Abstract
Peg-interferon alpha-2a and 2b and ribavirin have become the mainstays of chronic hepatitis C treatment. Although various cutaneous side effects have been reported, alopecia areata in its various forms have rare reports and has not been well categorized. Here we present a case of alopecia universalis occurring shortly after treatment for chronic hepatitis C, and we discuss some of the implications this has in understanding the pathophysiology of alopecia areata.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Alopecia / chemically induced
-
Alopecia / complications*
-
Antiviral Agents / therapeutic use
-
Drug Therapy, Combination
-
Hepatitis C, Chronic / complications
-
Hepatitis C, Chronic / drug therapy*
-
Humans
-
Interferon-alpha / therapeutic use
-
Male
-
Middle Aged
-
Oligopeptides / therapeutic use
-
Polyethylene Glycols / therapeutic use
-
Recombinant Proteins / therapeutic use
-
Ribavirin / therapeutic use
-
Withholding Treatment
Substances
-
Antiviral Agents
-
Interferon-alpha
-
Oligopeptides
-
Recombinant Proteins
-
Polyethylene Glycols
-
Ribavirin
-
telaprevir
-
peginterferon alfa-2a